• Celine van de Laar:  Cost-effectiveness of a JAK1/JAK2-inhibitor vs. a biologic disease-modifying antirheumatic drug in a treat-to-target strategy for rheumatoid arthritis. EULAR Congress.
  • Esther Beckers: Dutch translation and psychometric properties of a patient reported experience measure (PREM) for patients with rheumatoid arthritis and spondyloarthritis. EULAR Congress.
  • Esther Beckers: Performance of the ankylosing spondylitis disease activity score (ASDAS) in patients with peripheral and axial spondyloarthritis in clinical practice. EULAR Congress.


  • Casper Webers: Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands. ACR Annual Meeting.
  • Peter ten Klooster: Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry. ACR Annual Meeting.


  • Celine van de Laar: Initial combination therapy versus step-up therapy is more effective and less costly as a treat to target strategy for RA: A Markov model based upon the Dutch Rheumatoid Arthritis Monitoring registry cohorts. ACR Annual Meeting.
  • Peter ten Klooster: Predictive value of a single measurement of the multi-biomarker disease activity (MBDA) score for disease flares within 6 and 12 months in rheumatoid arthritis patients using tumor necrosis factor inhibitors and conventional synthetic dmards. EULAR Congress.
  • Laura Steunebrink: Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat to target therapy in daily clinical practice: results from the DREAM registry. EULAR Congress.


  • Laura Steunebrink: Early radiological progression in rheumatoid arthritis leads to more long-term joint damage in daily clinical practice; Six year radiological outcomes of a strict treat-to-target cohort in the Netherlands. ACR Annual Meeting.
  • Marjan Ghiti: Clinical predictors of TNF-inhibitor free disease control in patients with rheumatoid arthritis after stopping TNFi treatment: Results from a Dutch multicentre pragmatic open-label randomized controlled trial. ACR Annual Meeting.




  • Marjan Ghiti: Eerste resultaten van POEET studie.
  • Femke Lamers-Karnebeek: De POET-US Studie: De eerste data.
  • Martijn Oude Voshaar: Predictors of no improvement in subjective health perception in newly diagnosed rheumatoid athritis patients with a good DAS28 response at 12 months in the Dutch Rheumatoid Arthritis Monitoring tight control cohort. ACR Annual Meeting.